索拉非尼联合卡培他滨治疗肝细胞肝癌的效果及对血清miR-212和miR-132水平的影响

Clinical effects of sorafenib combined with capecitabine on hepatocellular carcinoma and its influence on serum miR-212 and miR-132 levels

目的探讨索拉非尼联合卡培他滨治疗肝细胞肝癌(HCC)的效果及对患者血清miR-212和miR-132水平的影响。方法抽取2018年2月至2020年6月郑州人民医院收治的HCC患者126例,采用随机数字表法分为单一组和联合组,每组63例。单一组给予卡培他滨治疗,联合组给予索拉非尼联合卡培他滨治疗。比较两组的化疗效果、近期生存率、血清miR-212和miR-132水平及不良反应发生率。结果联合组总有效率(79.36%,50/63)高于单一组(61.90%,39/60),P<0.05。治疗后,两组血清miR-212和miR-132 mRNA、蛋白水平高于治疗前,且联合组高于单一组(P<0.05);治疗后1年,联合组无进展生存率为73.02%(46/63),高于单一组的52.38%(33/63),P<0.05。联合组不良反应总发生率(26.98%,17/63)与单一组(17.46%,11/63)比较差异未见统计学意义(P>0.05)。结论索拉非尼联合卡培他滨治疗HCC在调节患者血清miR-212和miR-132水平、提高疗效和近期生存率方面有积极作用,且联合用药未明显增加不良反应的发生。

Objective To investigate the curative effects of sorafenib combined with capecitabine in the treatment of hepatocellular carcinoma(HCC),and the influence on serum miR-212 and miR-132 levels.Methods A total of 126 patients with HCC treated in Zhengzhou People’s Hospital from February 2018 to June 2020 were selected.They were divided into single group and combination group by random number table method,with 63 cases in each group.Patients in single group were treatment with capecitabine,and patients in combination group were treatment with sorafenib combined with capecitabine.The curative effect of chemotherapy,short-term survival rate,serum miR-212 and miR-132 levels,and the incidence of adverse reactions were compared between the two groups.Results The total response rate in combination group(79.36%,50/63)was higher than that in single group(61.90%,39/60),P<0.05.After treatment,the mRNA and protein levels of miR-212 or miR-132 were significantly increased in the two groups,and the levels in combination group were significantly higher than those in single group(P<0.05).The progression-free survival rate in combination group(73.02%,46/63)was significantly higher than that in single group(52.38%,33/63)1 year after treatment(P<0.05).There was no significant difference in incidence of adverse reactions between combination group(26.98%,17/63)and single group(17.46%,11/63),P>0.05.Conclusions Sorafenib combined with capecitabine plays a significant positive role in regulating serum miR-212 and miR-132 levels,and improving curative effect and short-term survival rate in patients with HCC,without significant increase in incidence of adverse reactions.